What We Do

Lilly unites caring with discovery to make life better for people around the world. We focus on five core global business areas: bio-medicines, diabetes, oncology, emerging markets and animal health. We also continue to pursue innovative science and new opportunities beyond our targeted disease categories.

Lilly Bio-Medicines comprises the largest of Lilly’s five business areas in terms of sales, and accounts for nearly half of Lilly’s mid-to-late stage pipeline assets, including autoimmunity, cardiovascular, musculoskeletal, neuroscience and urology.

Lilly remains committed to meeting the needs of people with diabetes; from medicines to support programmes, including investing in one of our largest diabetes pipelines ever.

As one of the top oncology companies in the world, Lilly focuses on speeding innovation and improving outcomes for individual patients, and boasts one of the largest clinical pipelines in the oncology industry.

Emerging Markets
We work to deliver innovative medicines that address unmet needs around the world. More than 6,000 employees in 30 Lilly affiliates work across the 70 countries that make up Lilly's Emerging Markets business.

Elanco Animal Health
A global division of Lilly, Elanco works to develop and market products that improve animal health and protein production in more than 75 countries across the globe.